Literature DB >> 25352046

Phenylketonuria: brain phenylalanine concentrations relate inversely to cerebral protein synthesis.

Martijn J de Groot1, Paul E Sijens2, Dirk-Jan Reijngoud3, Anne M Paans4, Francjan J van Spronsen1.   

Abstract

In phenylketonuria, elevated plasma phenylalanine concentrations may disturb blood-to-brain large neutral amino acid (LNAA) transport and cerebral protein synthesis (CPS). We investigated the associations between these processes, using data obtained by positron emission tomography with l-[1-(11)C]-tyrosine ((11)C-Tyr) as a tracer. Blood-to-brain transport of non-Phe LNAAs was modeled by the rate constant for (11)C-Tyr transport from arterial plasma to brain tissue (K1), while CPS was modeled by the rate constant for (11)C-Tyr incorporation into cerebral protein (k3). Brain phenylalanine concentrations were measured by magnetic resonance spectroscopy in three volumes of interest (VOIs): supraventricular brain tissue (VOI 1), ventricular brain tissue (VOI 2), and fluid-containing ventricular voxels (VOI 3). The associations between k3 and each predictor variable were analyzed by multiple linear regression. The rate constant k3 was inversely associated with brain phenylalanine concentrations in VOIs 2 and 3 (adjusted R(2)=0.826, F=19.936, P=0.021). Since brain phenylalanine concentrations in these VOIs highly correlated with each other, the specific associations of each predictor with k3 could not be determined. The associations between k3 and plasma phenylalanine concentration, K1, and brain phenylalanine concentrations in VOI 1 were nonsignificant. In conclusion, our study shows an inverse association between k3 and increased brain phenylalanine concentrations.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25352046      PMCID: PMC4426736          DOI: 10.1038/jcbfm.2014.183

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  38 in total

1.  In vivo NMR spectroscopy in patients with phenylketonuria: clinical significance of interindividual differences in brain phenylalanine concentrations.

Authors:  J Weglage; H E Möller; D Wiedermann; S Cipcic-Schmidt; J Zschocke; K Ullrich
Journal:  J Inherit Metab Dis       Date:  1998-02       Impact factor: 4.982

Review 2.  Blood-brain barrier carrier-mediated transport and brain metabolism of amino acids.

Authors:  W M Pardridge
Journal:  Neurochem Res       Date:  1998-05       Impact factor: 3.996

3.  Estimation of local cerebral protein synthesis rates with L-[1-11C]leucine and PET: methods, model, and results in animals and humans.

Authors:  R A Hawkins; S C Huang; J R Barrio; R E Keen; D Feng; J C Mazziotta; M E Phelps
Journal:  J Cereb Blood Flow Metab       Date:  1989-08       Impact factor: 6.200

4.  [3H]DOPA formed from [3H]tyrosine in living rat brain is not committed to dopamine synthesis.

Authors:  P Cumming; A Ase; H Kuwabara; A Gjedde
Journal:  J Cereb Blood Flow Metab       Date:  1998-05       Impact factor: 6.200

5.  Kinetics of phenylalanine transport at the human blood-brain barrier investigated in vivo.

Authors:  H E Möller; J Weglage; D Wiedermann; P Vermathen; U Bick; K Ullrich
Journal:  Brain Res       Date:  1997-12-19       Impact factor: 3.252

6.  Blood-brain barrier transport of amino acids in healthy controls and in patients with phenylketonuria.

Authors:  G M Knudsen; S Hasselbalch; P B Toft; E Christensen; O B Paulson; H Lou
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

7.  Comparison of L-[1-11C]methionine and L-methyl-[11C]methionine for measuring in vivo protein synthesis rates with PET.

Authors:  K Ishiwata; W Vaalburg; P H Elsinga; A M Paans; M G Woldring
Journal:  J Nucl Med       Date:  1988-08       Impact factor: 10.057

8.  Neurotransmitter positron emission tomographic-studies in adults with phenylketonuria, a pilot study.

Authors:  A M Paans; J Pruim; G P Smit; G Visser; A T Willemsen; K Ullrich
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

9.  In vivo protein synthesis rate determination in primary or recurrent brain tumors using L-[1-11C]-tyrosine and PET.

Authors:  A T Willemsen; A van Waarde; A M Paans; J Pruim; G Luurtsema; K G Go; W Vaalburg
Journal:  J Nucl Med       Date:  1995-03       Impact factor: 10.057

10.  Phenylketonuria: reduced tyrosine brain influx relates to reduced cerebral protein synthesis.

Authors:  Martijn J de Groot; Marieke Hoeksma; Dirk-Jan Reijngoud; Harold W de Valk; Anne M J Paans; Pieter J J Sauer; Francjan J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2013-09-04       Impact factor: 4.123

View more
  7 in total

Review 1.  Phenylketonuria Pathophysiology: on the Role of Metabolic Alterations.

Authors:  Patrícia Fernanda Schuck; Fernanda Malgarin; José Henrique Cararo; Fabiola Cardoso; Emilio Luiz Streck; Gustavo Costa Ferreira
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

2.  A Multiplatform Metabolomics Approach to Characterize Plasma Levels of Phenylalanine and Tyrosine in Phenylketonuria.

Authors:  H Blasco; C Veyrat-Durebex; M Bertrand; F Patin; F Labarthe; H Henique; P Emond; C R Andres; C Antar; C Landon; L Nadal-Desbarats; F Maillot
Journal:  JIMD Rep       Date:  2016-06-15

Review 3.  In Vivo NMR Studies of the Brain with Hereditary or Acquired Metabolic Disorders.

Authors:  Erica B Sherry; Phil Lee; In-Young Choi
Journal:  Neurochem Res       Date:  2015-11-26       Impact factor: 3.996

4.  Large Neutral Amino Acid Supplementation Exerts Its Effect through Three Synergistic Mechanisms: Proof of Principle in Phenylketonuria Mice.

Authors:  Danique van Vliet; Vibeke M Bruinenberg; Priscila N Mazzola; Martijn H J R van Faassen; Pim de Blaauw; Ido P Kema; M Rebecca Heiner-Fokkema; Rogier D van Anholt; Eddy A van der Zee; Francjan J van Spronsen
Journal:  PLoS One       Date:  2015-12-01       Impact factor: 3.240

5.  Patient's thoughts and expectations about centres of expertise for PKU.

Authors:  A M J van Wegberg; A MacDonald; D Abeln; T S Hagedorn; E Lange; F Trefz; D van Vliet; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2021-01-06       Impact factor: 4.123

6.  L-carnitine protects DNA oxidative damage induced by phenylalanine and its keto acid derivatives in neural cells: a possible pathomechanism and adjuvant therapy for brain injury in phenylketonuria.

Authors:  Jéssica Lamberty Faverzani; Aline Steinmetz; Marion Deon; Desirèe Padilha Marchetti; Gilian Guerreiro; Angela Sitta; Daniella de Moura Coelho; Franciele Fatima Lopes; Leopoldo Vinicius Martins Nascimento; Luiza Steffens; Jeferson Gustavo Henn; Matheus Bernardes Ferro; Verônica Bidinotto Brito; Moacir Wajner; Dinara Jaqueline Moura; Carmen Regla Vargas
Journal:  Metab Brain Dis       Date:  2021-07-03       Impact factor: 3.584

7.  Optimising amino acid absorption: essential to improve nitrogen balance and metabolic control in phenylketonuria.

Authors:  Anita MacDonald; Rani H Singh; Júlio César Rocha; Francjan J van Spronsen
Journal:  Nutr Res Rev       Date:  2018-10-04       Impact factor: 7.800

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.